Skip to main content
Bliss GVS Pharma Limited logo

Bliss GVS Pharma Limited — Investor Relations & Filings

Ticker · BLISSGVS ISIN · INE416D01022 LEI · 335800GXY3YCGGP7KJ45 BSE.NS Manufacturing
Open in API
Filings indexed 1,243 across all filing types
Latest filing 2024-03-18 Regulatory Filings
Country IN India
Listing BSE.NS BLISSGVS

About Bliss GVS Pharma Limited

https://blissgvs.com/

Bliss GVS Pharma Limited specializes in the development, manufacturing, and marketing of diverse pharmaceutical formulations. The company is a global leader in the production of suppositories and pessaries, maintaining an extensive portfolio within these specialized dosage forms. Its therapeutic focus includes anti-malarials, anti-fungals, anti-bacterials, anti-inflammatories, and gastrointestinal treatments. The organization operates state-of-the-art manufacturing facilities compliant with international quality standards, including WHO-GMP. With a strategic focus on emerging markets, the company distributes its range of prescription and over-the-counter products across Sub-Saharan Africa, Southeast Asia, and Latin America, leveraging a robust supply chain to provide accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a formal communication addressed to stock exchanges regarding the loss of share certificates and the issuance of duplicate share certificates. It references compliance with SEBI regulations and requests brokers not to deal with the lost certificates. There is no financial data, report, or analysis presented. The document is an official regulatory announcement related to share certificates, fitting the category of a Regulatory Filing (RNS) rather than a financial report or other specific filing type.
2024-03-18 English
Pursuant to Regulation 39(3) of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that our Registrar and Transfer ....
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (NSE and BSE) regarding the loss of share certificates and the issuance of duplicate share certificates. It references compliance with SEBI regulations and requests brokers not to deal with the lost certificates. The content is an announcement related to share certificates and regulatory compliance, not a financial report, earnings release, or management discussion. It does not contain financial data or detailed report content but is a regulatory notification about share certificate status. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-03-18 English
Restructuring
Capital/Financing Update Classification · 95% confidence The document is an official communication addressed to stock exchanges (NSE and BSE) regarding an internal restructuring of subsidiaries of Bliss GVS Pharma Limited. It references compliance with SEBI Listing Regulations, specifically Regulation 30, which mandates disclosure of material events. The content details changes in ownership, voluntary closure of a subsidiary, and conversion of loans into equity shares within the group. It includes annexures with detailed information about these transactions. The document is dated February 16, 2024, and is a formal intimation of corporate actions rather than a financial report or earnings release. There is no presentation of financial statements or detailed financial performance analysis. The document is a regulatory disclosure about corporate restructuring activities, fitting the category of Capital/Financing Update (CAP) as it relates to changes in capital structure and subsidiary ownership within the group.
2024-02-16 English
The Board of Directors of the Company has approved an internal restruturing of foreign subsidiaries of the Company.
Regulatory Filings Classification · 95% confidence The document is an official communication addressed to stock exchanges (NSE and BSE) regarding an internal restructuring of subsidiaries of Bliss GVS Pharma Limited. It references compliance with SEBI Listing Regulations, specifically Regulation 30, which mandates disclosure of material events. The content details changes in ownership, voluntary closure of a subsidiary, and conversion of loans into equity shares within the group. It includes annexures with detailed information about these transactions. The document is not a financial report, earnings release, or management discussion but a regulatory disclosure about corporate restructuring events. It is a regulatory announcement under SEBI LODR requirements, fitting the category of Regulatory Filings (RNS). The document length and detail confirm it is not a brief announcement or a report publication notice but a substantive regulatory disclosure.
2024-02-16 English
The Board of Directors of the Company has approved an internal restruturing of foreign subsidiaries of the Company.
Regulatory Filings Classification · 95% confidence The document is an official intimation to stock exchanges (NSE and BSE) regarding an internal restructuring of subsidiaries of Bliss GVS Pharma Limited. It references compliance with SEBI Listing Regulations, specifically Regulation 30, which pertains to disclosure of material events. The content details changes in ownership within subsidiaries, voluntary closure of a subsidiary, and conversion of loans into equity shares. It includes annexures with detailed information about these transactions. The document is dated February 16, 2024, and is addressed to the listing departments of stock exchanges, indicating it is a regulatory disclosure. It does not contain financial statements or comprehensive financial performance data, nor is it a report like an annual or interim report. It is not a call transcript, earnings release, or governance report. The document is a formal announcement of corporate restructuring activities and related party transactions, fitting the category of a Regulatory Filing (RNS) under SEBI regulations. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-02-16 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a formal notification addressed to stock exchanges regarding the loss of a share certificate and the issuance of a duplicate share certificate. It references compliance with SEBI regulations and requests brokers not to deal with the lost certificate. The content is about share certificate status and regulatory compliance, not a financial report, earnings release, or management discussion. It does not contain financial data or results, nor is it a report publication announcement. This type of document fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements and compliance documents that do not fit other categories.
2024-02-06 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.